Response to Final Office action mailed 10/15/2007

Applicant: THIERFELDER et al.

Serial No.: 10/636,182 Filed: August 7, 2003

For: DRUG DELIVERY DEVICE AND METHOD

Examiner: Gilbert, Andrew M.
Group Art Unit: 3767
Docket No.: AMS0091/US

## **Amendments to the Claims**

This Listing of Claims, as amended below, replaces all previous listings.

## **Listing of Claims**

Claims 1-12. (Cancelled)

Claim 13. (Currently Amended) An implantable drug delivery system comprising:

a storage area for storing a drug,

a meter for metering a predetermined, effective amount of the drug;

delivery means for delivering the effective amount of the drug to a patient to treat a disorder, the delivery means comprising:

a catheter having a plurality of drug delivery ports, the drug delivery ports being movable between an open position to deliver the drug to the patient, and a closed position; and

drug delivery path preservation means <u>comprising a coating on the catheter</u> for <u>interacting with fibrous occlusion-forming substances to resist</u> <del>delivering a substance to the ports for resisting</del> fibrous occlusion of the drug delivery ports, the drug delivery preservation means being proximate the drug delivery ports.

- Claim 14. (Currently Amended) An implantable drug delivery system according to claim 13-, wherein the coating substance for resisting fibrous occlusions comprises poly(glycine-valine-glycine-valine-proline).
- Claim 15. (Previously Presented) An implantable drug delivery system according to claim 13, wherein the catheter has a longitudinal axis and the drug delivery ports comprise a plurality of slits.
- Claim 16. (Currently Amended) An implantable drug delivery system according to claim 13, wherein the coating substance for resisting fibrous occlusions in the drug delivery ports comprises a material selected from the group consisting of connective tissue growth blocker, C-Proteinase blocker, prolyl hydroxylase blocker, poly(glycine-valine-glycine-valine-proline), and polylacticglycolic acid microspheres including dexamethasone.

Claims 17-20. (Cancelled)